APO Research
Talk to an analyst

APO RESEARCH · REPORT

Microbiome Therapeutics

The human microbiome is the collection of all the microorganisms living in association with the human body. These communities consist of a variety of microorganisms including eukaryotes, archaea, bacteria and viruses. Bacteria in an average human body number ten times more than human cells, for a total of about 1000 more genes than are present in the human genome. Because of their small size, however, microorganisms make up only about 1 to 3 percent of our body mass (that's 2 to 6 pounds of bacteria in a 200-pound adult).

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

The human microbiome is the collection of all the microorganisms living in association with the human body. These communities consist of a variety of microorganisms including eukaryotes, archaea, bacteria and viruses. Bacteria in an average human body number ten times more than human cells, for a total of about 1000 more genes than are present in the human genome. Because of their small size, however, microorganisms make up only about 1 to 3 percent of our body mass (that's 2 to 6 pounds of bacteria in a 200-pound adult).

These microbes are generally not harmful to us; in fact they are essential for maintaining health. For example, they produce some vitamins that we do not have the genes to make, break down our food to extract nutrients we need to survive, teach our immune systems how to recognize dangerous invaders and even produce helpful anti-inflammatory compounds that fight off other disease-causing microbes.

An ever-growing number of studies have demonstrated that changes in the composition of our microbiomes correlate with numerous disease states, raising the possibility that manipulation of these communities could be used to treat disease.

Selected research

Market Outlook & Growth Opportunities

Global Microbiome Therapeutics Market Outlook and Growth Opportunities 2026

2 January 2026213 pages

Choose your research edition.

Industry ResearchMicrobiome Therapeutics Industry Research Report 2026144 pages · $2,950 USDIndustry Growth & TrendsGlobal Microbiome Therapeutics Industry Growth and Trends Forecast to 2032121 pages · $3,450 USDMarket StructureGlobal Microbiome Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Microbiome Therapeutics Market Outlook and Growth Opportunities 2026213 pages · $4,250 USDMarket Analysis & ForecastGlobal Microbiome Therapeutics Market Analysis and Forecast 2026-2032211 pages · $4,950 USD

Market perspective

The human microbiome is the collection of all the microorganisms living in association with the human body. These communities consist of a variety of microorganisms including eukaryotes, archaea, bacteria and viruses. Bacteria in an average human body number ten times more than human cells, for a total of about 1000 more genes than are present in the human genome. Because of their small size, however, microorganisms make up only about 1 to 3 percent of our body mass (that's 2 to 6 pounds of bacteria in a 200-pound adult).

These microbes are generally not harmful to us; in fact they are essential for maintaining health. For example, they produce some vitamins that we do not have the genes to make, break down our food to extract nutrients we need to survive, teach our immune systems how to recognize dangerous invaders and even produce helpful anti-inflammatory compounds that fight off other disease-causing microbes.

An ever-growing number of studies have demonstrated that changes in the composition of our microbiomes correlate with numerous disease states, raising the possibility that manipulation of these communities could be used to treat disease.

Read the full market overview

The Application of Microbiome Therapeutics includes CDI, IBD, Orphan Drug, Immuno-oncology and Others, and the proportion of R&D Investmen for CDI is about 52%.

For Microbiome Therapeutics Pipeline Product, SER-109, ABI-H0731, ribaxamase, SYN-010 have the most investment in research, there are in Phase 3, PHASE 1b and Phase 2.

North American is the largest market, It occupy nearly 37% market share. Following North American, Europe is the second largest market with the consumption market share of 30%.

Market competition is not intense. Seres Therapeutics, Assembly Biosciences, Synthetic Biologics, Interxon and PureTech are the leading Developers in the industry, with about 60% market shares.

This report provides an overview of the global Microbiome Therapeutics market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Microbiome Therapeutics and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Microbiome Therapeutics revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Microbiome Therapeutics market.

Microbiome Therapeutics Segment by Company

Seres Therapeutics

Assembly Biosciences

Synthetic Biologics

Interxon

PureTech

Synlogic

Enterome BioScience

4D Pharma

Second Genome

AOBiome

C3 Jian

Rebiotix

MicroBiome Therapeutics LLC

Metabiomics

Ritter Pharmaceuticals

Symberix

OpenBiome

Azitra

Symbiotix Biotherapies

Osel

Metabogen

Microbiome Therapeutics Segment by Type

Upper GIT

Lower GIT

Microbiome Therapeutics Segment by Application

C. difficile Infection (CDI)

Inflammatory Bowel Disease (IBD)

Orphan Drug

Immuno-oncology

Others

Microbiome Therapeutics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Microbiome Therapeutics status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Microbiome Therapeutics key companies, revenue, market share, and recent developments.

3. To split the Microbiome Therapeutics breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Microbiome Therapeutics market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Microbiome Therapeutics significant trends, drivers, influence factors in global and regions.

6. To analyze Microbiome Therapeutics competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Microbiome Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Microbiome Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Microbiome Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Microbiome Therapeutics industry.

Chapter 3: Detailed analysis of Microbiome Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Microbiome Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Microbiome Therapeutics in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Microbiome Therapeutics Industry Trends Table 2. Microbiome Therapeutics Industry Drivers Table 3. Microbiome Therapeutics Industry Opportunities and Challenges Table 4. Microbiome Therapeutics Industry Restraints Table 5. Global Microbiome Therapeutics Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Microbiome Therapeutics Revenue Share by Company (2021-2026) Table 7. Global Microbiome Therapeutics Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Microbiome Therapeutics Key Company Manufacturing Base & Headquarters Table 9. Global Microbiome Therapeutics Company, Product Type & Application Table 10. Global Microbiome Therapeutics Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Microbiome Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Upper GIT Table 15. Significant Companies of Lower GIT Table 16. Global Microbiome Therapeutics Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Microbiome Therapeutics Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Microbiome Therapeutics Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Microbiome Therapeutics Sales Value Share by Type (2021-2026) Table 20. Global Microbiome Therapeutics Sales Value Share by Type (2027-2032) Table 21. Significant Companies of C. difficile Infection (CDI) Table 22. Significant Companies of Inflammatory Bowel Disease (IBD) Table 23. Significant Companies of Orphan Drug Table 24. Significant Companies of Immuno-oncology Table 25. Significant Companies of Others Table 26. Global Microbiome Therapeutics Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Microbiome Therapeutics Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Microbiome Therapeutics Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Microbiome Therapeutics Sales Value Share by Application (2021-2026) Table 30. Global Microbiome Therapeutics Sales Value Share by Application (2027-2032) Table 31. Global Microbiome Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Microbiome Therapeutics Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Microbiome Therapeutics Sales Value Share by Region (2021-2026) Table 34. Global Microbiome Therapeutics Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Microbiome Therapeutics Sales Value Share by Region (2027-2032) Table 36. Global Microbiome Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Microbiome Therapeutics Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Microbiome Therapeutics Sales Value Market Share by Country (2021-2026) Table 39. Global Microbiome Therapeutics Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Microbiome Therapeutics Sales Value Market Share by Country (2027-2032) Table 41. Seres Therapeutics Company Information Table 42. Seres Therapeutics Business Overview Table 43. Seres Therapeutics Microbiome Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Seres Therapeutics Microbiome Therapeutics Product Portfolio Table 45. Seres Therapeutics Recent Development Table 46. Assembly Biosciences Company Information Table 47. Assembly Biosciences Business Overview Table 48. Assembly Biosciences Microbiome Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Assembly Biosciences Microbiome Therapeutics Product Portfolio Table 50. Assembly Biosciences Recent Development Table 51. Synthetic Biologics Company Information Table 52. Synthetic Biologics Business Overview Table 53. Synthetic Biologics Microbiome Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Synthetic Biologics Microbiome Therapeutics Product Portfolio Table 55. Synthetic Biologics Recent Development Table 56. Interxon Company Information Table 57. Interxon Business Overview Table 58. Interxon Microbiome Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Interxon Microbiome Therapeutics Product Portfolio Table 60. Interxon Recent Development Table 61. PureTech Company Information Table 62. PureTech Business Overview Table 63. PureTech Microbiome Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. PureTech Microbiome Therapeutics Product Portfolio Table 65. PureTech Recent Development Table 66. Synlogic Company Information Table 67. Synlogic Business Overview Table 68. Synlogic Microbiome Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Synlogic Microbiome Therapeutics Product Portfolio Table 70. Synlogic Recent Development Table 71. Enterome BioScience Company Information Table 72. Enterome BioScience Business Overview Table 73. Enterome BioScience Microbiome Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Enterome BioScience Microbiome Therapeutics Product Portfolio Table 75. Enterome BioScience Recent Development Table 76. 4D Pharma Company Information Table 77. 4D Pharma Business Overview Table 78. 4D Pharma Microbiome Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. 4D Pharma Microbiome Therapeutics Product Portfolio Table 80. 4D Pharma Recent Development Table 81. Second Genome Company Information Table 82. Second Genome Business Overview Table 83. Second Genome Microbiome Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Second Genome Microbiome Therapeutics Product Portfolio Table 85. Second Genome Recent Development Table 86. AOBiome Company Information Table 87. AOBiome Business Overview Table 88. AOBiome Microbiome Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. AOBiome Microbiome Therapeutics Product Portfolio Table 90. AOBiome Recent Development Table 91. C3 Jian Company Information Table 92. C3 Jian Business Overview Table 93. C3 Jian Microbiome Therapeutics Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 94. C3 Jian Microbiome Therapeutics Product Portfolio Table 95. C3 Jian Recent Development Table 96. Rebiotix Company Information Table 97. Rebiotix Business Overview Table 98. Rebiotix Microbiome Therapeutics Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 99. Rebiotix Microbiome Therapeutics Product Portfolio Table 100. Rebiotix Recent Development Table 101. MicroBiome Therapeutics LLC Company Information Table 102. MicroBiome Therapeutics LLC Business Overview Table 103. MicroBiome Therapeutics LLC Microbiome Therapeutics Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 104. MicroBiome Therapeutics LLC Microbiome Therapeutics Product Portfolio Table 105. MicroBiome Therapeutics LLC Recent Development Table 106. Metabiomics Company Information Table 107. Metabiomics Business Overview Table 108. Metabiomics Microbiome Therapeutics Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 109. Metabiomics Microbiome Therapeutics Product Portfolio Table 110. Metabiomics Recent Development Table 111. Ritter Pharmaceuticals Company Information Table 112. Ritter Pharmaceuticals Business Overview Table 113. Ritter Pharmaceuticals Microbiome Therapeutics Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 114. Ritter Pharmaceuticals Microbiome Therapeutics Product Portfolio Table 115. Ritter Pharmaceuticals Recent Development Table 116. Symberix Company Information Table 117. Symberix Business Overview Table 118. Symberix Microbiome Therapeutics Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 119. Symberix Microbiome Therapeutics Product Portfolio Table 120. Symberix Recent Development Table 121. OpenBiome Company Information Table 122. OpenBiome Business Overview Table 123. OpenBiome Microbiome Therapeutics Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 124. OpenBiome Microbiome Therapeutics Product Portfolio Table 125. OpenBiome Recent Development Table 126. Azitra Company Information Table 127. Azitra Business Overview Table 128. Azitra Microbiome Therapeutics Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 129. Azitra Microbiome Therapeutics Product Portfolio Table 130. Azitra Recent Development Table 131. Symbiotix Biotherapies Company Information Table 132. Symbiotix Biotherapies Business Overview Table 133. Symbiotix Biotherapies Microbiome Therapeutics Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 134. Symbiotix Biotherapies Microbiome Therapeutics Product Portfolio Table 135. Symbiotix Biotherapies Recent Development Table 136. Osel Company Information Table 137. Osel Business Overview Table 138. Osel Microbiome Therapeutics Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 139. Osel Microbiome Therapeutics Product Portfolio Table 140. Osel Recent Development Table 141. Metabogen Company Information Table 142. Metabogen Business Overview Table 143. Metabogen Microbiome Therapeutics Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 144. Metabogen Microbiome Therapeutics Product Portfolio Table 145. Metabogen Recent Development Table 146. Research Programs/Design for This Report Table 147. Authors List of This Report Table 148. Secondary Sources Table 149. Primary Sources List of Figures Figure 1. Microbiome Therapeutics Product Image Figure 2. Global Microbiome Therapeutics Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Microbiome Therapeutics Market Size (2021-2032) & (US$ Million) Figure 4. Global Microbiome Therapeutics Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Upper GIT Image Figure 8. Lower GIT Image Figure 9. Global Microbiome Therapeutics Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Microbiome Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Microbiome Therapeutics Sales Value Share by Type (2021-2032) Figure 12. C. difficile Infection (CDI) Image Figure 13. Inflammatory Bowel Disease (IBD) Image Figure 14. Orphan Drug Image Figure 15. Immuno-oncology Image Figure 16. Others Image Figure 17. Global Microbiome Therapeutics Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Microbiome Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Microbiome Therapeutics Sales Value Share by Application (2021-2032) Figure 20. Global Microbiome Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Microbiome Therapeutics Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Microbiome Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 23. North America Microbiome Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Microbiome Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Microbiome Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Microbiome Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Microbiome Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Microbiome Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 29. South America Microbiome Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Microbiome Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Microbiome Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Microbiome Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Microbiome Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Microbiome Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Microbiome Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Microbiome Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Microbiome Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Microbiome Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Microbiome Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Microbiome Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Microbiome Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Microbiome Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Microbiome Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Microbiome Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Microbiome Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Microbiome Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Microbiome Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Microbiome Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Microbiome Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Microbiome Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Microbiome Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Microbiome Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Microbiome Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Microbiome Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Microbiome Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Microbiome Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Microbiome Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Microbiome Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Microbiome Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Microbiome Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Microbiome Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Microbiome Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Microbiome Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Microbiome Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Microbiome Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Microbiome Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Microbiome Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Microbiome Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Microbiome Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Microbiome Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Microbiome Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Microbiome Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Microbiome Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Microbiome Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Microbiome Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Microbiome Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Microbiome Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Microbiome Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Microbiome Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Microbiome Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Microbiome Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Microbiome Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Microbiome Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Microbiome Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Microbiome Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Microbiome Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Microbiome Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Microbiome Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Microbiome Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Microbiome Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Microbiome Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Microbiome Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Microbiome Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Microbiome Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Microbiome Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Microbiome Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Microbiome Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Microbiome Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Microbiome Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Microbiome Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Microbiome Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Microbiome Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Microbiome Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Microbiome Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Microbiome Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Microbiome Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Microbiome Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Microbiome Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Microbiome Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Microbiome Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Microbiome Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Microbiome Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Microbiome Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Microbiome Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Microbiome Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Upper GIT
  • Lower GIT
Applications
  • C. difficile Infection (CDI)
  • Inflammatory Bowel Disease (IBD)
  • Orphan Drug
  • Immuno-oncology
  • Others
Companies covered
  • Seres Therapeutics
  • Assembly Biosciences
  • Synthetic Biologics
  • Interxon
  • PureTech
  • Synlogic
  • Enterome BioScience
  • 4D Pharma
  • Second Genome
  • AOBiome
  • C3 Jian
  • Rebiotix
  • MicroBiome Therapeutics LLC
  • Metabiomics
  • Ritter Pharmaceuticals
  • Symberix
  • OpenBiome
  • Azitra
  • Symbiotix Biotherapies
  • Osel
  • Metabogen

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Microbiome Therapeutics Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Microbiome Therapeutics Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Microbiome Therapeutics Market Dynamics
  1. 2.1 Microbiome Therapeutics Industry Trends
  2. 2.2 Microbiome Therapeutics Industry Drivers
  3. 2.3 Microbiome Therapeutics Industry Opportunities and Challenges
  4. 2.4 Microbiome Therapeutics Industry Restraints
3 Microbiome Therapeutics Market by Company
  1. 3.1 Global Microbiome Therapeutics Company Revenue Ranking in 2025
  2. 3.2 Global Microbiome Therapeutics Revenue by Company (2021-2026)
  3. 3.3 Global Microbiome Therapeutics Company Ranking (2024-2026)
  4. 3.4 Global Microbiome Therapeutics Company Manufacturing Base and Headquarters
  5. 3.5 Global Microbiome Therapeutics Company Product Type and Application
  6. 3.6 Global Microbiome Therapeutics Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Microbiome Therapeutics Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Microbiome Therapeutics Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Microbiome Therapeutics Market by Type
  1. 4.1 Microbiome Therapeutics Type Introduction
  2. 4.1.1 Upper GIT
  3. 4.1.2 Lower GIT
  4. 4.2 Global Microbiome Therapeutics Sales Value by Type
  5. 4.2.1 Global Microbiome Therapeutics Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Microbiome Therapeutics Sales Value by Type (2021-2032)
  7. 4.2.3 Global Microbiome Therapeutics Sales Value Share by Type (2021-2032)
5 Microbiome Therapeutics Market by Application
  1. 5.1 Microbiome Therapeutics Application Introduction
  2. 5.1.1 C. difficile Infection (CDI)
  3. 5.1.2 Inflammatory Bowel Disease (IBD)
  4. 5.1.3 Orphan Drug
  5. 5.1.4 Immuno-oncology
  6. 5.1.5 Others
  7. 5.2 Global Microbiome Therapeutics Sales Value by Application
  8. 5.2.1 Global Microbiome Therapeutics Sales Value by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Microbiome Therapeutics Sales Value by Application (2021-2032)
  10. 5.2.3 Global Microbiome Therapeutics Sales Value Share by Application (2021-2032)
6 Microbiome Therapeutics Regional Value Analysis
  1. 6.1 Global Microbiome Therapeutics Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Microbiome Therapeutics Sales Value by Region (2021-2032)
  3. 6.2.1 Global Microbiome Therapeutics Sales Value by Region: 2021-2026
  4. 6.2.2 Global Microbiome Therapeutics Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Microbiome Therapeutics Sales Value (2021-2032)
  7. 6.3.2 North America Microbiome Therapeutics Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Microbiome Therapeutics Sales Value (2021-2032)
  10. 6.4.2 Europe Microbiome Therapeutics Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Microbiome Therapeutics Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Microbiome Therapeutics Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Microbiome Therapeutics Sales Value (2021-2032)
  16. 6.6.2 South America Microbiome Therapeutics Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Microbiome Therapeutics Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Microbiome Therapeutics Sales Value Share by Country, 2025 VS 2032
7 Microbiome Therapeutics Country-level Value Analysis
  1. 7.1 Global Microbiome Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Microbiome Therapeutics Sales Value by Country (2021-2032)
  3. 7.2.1 Global Microbiome Therapeutics Sales Value by Country (2021-2026)
  4. 7.2.2 Global Microbiome Therapeutics Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Microbiome Therapeutics Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Microbiome Therapeutics Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Microbiome Therapeutics Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Microbiome Therapeutics Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Microbiome Therapeutics Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Microbiome Therapeutics Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Microbiome Therapeutics Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Microbiome Therapeutics Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Microbiome Therapeutics Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Microbiome Therapeutics Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Microbiome Therapeutics Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Microbiome Therapeutics Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Microbiome Therapeutics Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Microbiome Therapeutics Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Microbiome Therapeutics Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Microbiome Therapeutics Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Microbiome Therapeutics Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Microbiome Therapeutics Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Microbiome Therapeutics Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Microbiome Therapeutics Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Microbiome Therapeutics Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Microbiome Therapeutics Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Microbiome Therapeutics Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Microbiome Therapeutics Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Microbiome Therapeutics Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Microbiome Therapeutics Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Microbiome Therapeutics Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Microbiome Therapeutics Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Microbiome Therapeutics Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Microbiome Therapeutics Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Microbiome Therapeutics Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Microbiome Therapeutics Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Microbiome Therapeutics Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Microbiome Therapeutics Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Microbiome Therapeutics Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Microbiome Therapeutics Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Microbiome Therapeutics Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Microbiome Therapeutics Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Microbiome Therapeutics Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Microbiome Therapeutics Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Microbiome Therapeutics Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Microbiome Therapeutics Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Microbiome Therapeutics Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Microbiome Therapeutics Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Microbiome Therapeutics Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Microbiome Therapeutics Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Microbiome Therapeutics Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Microbiome Therapeutics Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Microbiome Therapeutics Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Microbiome Therapeutics Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Microbiome Therapeutics Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Microbiome Therapeutics Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Microbiome Therapeutics Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Microbiome Therapeutics Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Microbiome Therapeutics Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Microbiome Therapeutics Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Microbiome Therapeutics Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Microbiome Therapeutics Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Microbiome Therapeutics Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Microbiome Therapeutics Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Microbiome Therapeutics Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Microbiome Therapeutics Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Microbiome Therapeutics Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Microbiome Therapeutics Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Microbiome Therapeutics Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Microbiome Therapeutics Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Microbiome Therapeutics Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Microbiome Therapeutics Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Microbiome Therapeutics Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Microbiome Therapeutics Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Microbiome Therapeutics Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Microbiome Therapeutics Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Microbiome Therapeutics Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Microbiome Therapeutics Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Microbiome Therapeutics Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Microbiome Therapeutics Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Microbiome Therapeutics Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Microbiome Therapeutics Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Microbiome Therapeutics Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Microbiome Therapeutics Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Microbiome Therapeutics Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Microbiome Therapeutics Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Microbiome Therapeutics Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Microbiome Therapeutics Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Seres Therapeutics
  2. 8.1.1 Seres Therapeutics Company Information
  3. 8.1.2 Seres Therapeutics Business Overview
  4. 8.1.3 Seres Therapeutics Microbiome Therapeutics Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Seres Therapeutics Microbiome Therapeutics Product Portfolio
  6. 8.1.5 Seres Therapeutics Recent Developments
  7. 8.2 Assembly Biosciences
  8. 8.2.1 Assembly Biosciences Company Information
  9. 8.2.2 Assembly Biosciences Business Overview
  10. 8.2.3 Assembly Biosciences Microbiome Therapeutics Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Assembly Biosciences Microbiome Therapeutics Product Portfolio
  12. 8.2.5 Assembly Biosciences Recent Developments
  13. 8.3 Synthetic Biologics
  14. 8.3.1 Synthetic Biologics Company Information
  15. 8.3.2 Synthetic Biologics Business Overview
  16. 8.3.3 Synthetic Biologics Microbiome Therapeutics Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Synthetic Biologics Microbiome Therapeutics Product Portfolio
  18. 8.3.5 Synthetic Biologics Recent Developments
  19. 8.4 Interxon
  20. 8.4.1 Interxon Company Information
  21. 8.4.2 Interxon Business Overview
  22. 8.4.3 Interxon Microbiome Therapeutics Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Interxon Microbiome Therapeutics Product Portfolio
  24. 8.4.5 Interxon Recent Developments
  25. 8.5 PureTech
  26. 8.5.1 PureTech Company Information
  27. 8.5.2 PureTech Business Overview
  28. 8.5.3 PureTech Microbiome Therapeutics Revenue and Gross Margin (2021-2026)
  29. 8.5.4 PureTech Microbiome Therapeutics Product Portfolio
  30. 8.5.5 PureTech Recent Developments
  31. 8.6 Synlogic
  32. 8.6.1 Synlogic Company Information
  33. 8.6.2 Synlogic Business Overview
  34. 8.6.3 Synlogic Microbiome Therapeutics Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Synlogic Microbiome Therapeutics Product Portfolio
  36. 8.6.5 Synlogic Recent Developments
  37. 8.7 Enterome BioScience
  38. 8.7.1 Enterome BioScience Company Information
  39. 8.7.2 Enterome BioScience Business Overview
  40. 8.7.3 Enterome BioScience Microbiome Therapeutics Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Enterome BioScience Microbiome Therapeutics Product Portfolio
  42. 8.7.5 Enterome BioScience Recent Developments
  43. 8.8 4D Pharma
  44. 8.8.1 4D Pharma Company Information
  45. 8.8.2 4D Pharma Business Overview
  46. 8.8.3 4D Pharma Microbiome Therapeutics Revenue and Gross Margin (2021-2026)
  47. 8.8.4 4D Pharma Microbiome Therapeutics Product Portfolio
  48. 8.8.5 4D Pharma Recent Developments
  49. 8.9 Second Genome
  50. 8.9.1 Second Genome Company Information
  51. 8.9.2 Second Genome Business Overview
  52. 8.9.3 Second Genome Microbiome Therapeutics Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Second Genome Microbiome Therapeutics Product Portfolio
  54. 8.9.5 Second Genome Recent Developments
  55. 8.10 AOBiome
  56. 8.10.1 AOBiome Company Information
  57. 8.10.2 AOBiome Business Overview
  58. 8.10.3 AOBiome Microbiome Therapeutics Revenue and Gross Margin (2021-2026)
  59. 8.10.4 AOBiome Microbiome Therapeutics Product Portfolio
  60. 8.10.5 AOBiome Recent Developments
  61. 8.11 C3 Jian
  62. 8.11.1 C3 Jian Company Information
  63. 8.11.2 C3 Jian Business Overview
  64. 8.11.3 C3 Jian Microbiome Therapeutics Revenue and Gross Margin (2021-2026)
  65. 8.11.4 C3 Jian Microbiome Therapeutics Product Portfolio
  66. 8.11.5 C3 Jian Recent Developments
  67. 8.12 Rebiotix
  68. 8.12.1 Rebiotix Company Information
  69. 8.12.2 Rebiotix Business Overview
  70. 8.12.3 Rebiotix Microbiome Therapeutics Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Rebiotix Microbiome Therapeutics Product Portfolio
  72. 8.12.5 Rebiotix Recent Developments
  73. 8.13 MicroBiome Therapeutics LLC
  74. 8.13.1 MicroBiome Therapeutics LLC Company Information
  75. 8.13.2 MicroBiome Therapeutics LLC Business Overview
  76. 8.13.3 MicroBiome Therapeutics LLC Microbiome Therapeutics Revenue and Gross Margin (2021-2026)
  77. 8.13.4 MicroBiome Therapeutics LLC Microbiome Therapeutics Product Portfolio
  78. 8.13.5 MicroBiome Therapeutics LLC Recent Developments
  79. 8.14 Metabiomics
  80. 8.14.1 Metabiomics Company Information
  81. 8.14.2 Metabiomics Business Overview
  82. 8.14.3 Metabiomics Microbiome Therapeutics Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Metabiomics Microbiome Therapeutics Product Portfolio
  84. 8.14.5 Metabiomics Recent Developments
  85. 8.15 Ritter Pharmaceuticals
  86. 8.15.1 Ritter Pharmaceuticals Company Information
  87. 8.15.2 Ritter Pharmaceuticals Business Overview
  88. 8.15.3 Ritter Pharmaceuticals Microbiome Therapeutics Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Ritter Pharmaceuticals Microbiome Therapeutics Product Portfolio
  90. 8.15.5 Ritter Pharmaceuticals Recent Developments
  91. 8.16 Symberix
  92. 8.16.1 Symberix Company Information
  93. 8.16.2 Symberix Business Overview
  94. 8.16.3 Symberix Microbiome Therapeutics Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Symberix Microbiome Therapeutics Product Portfolio
  96. 8.16.5 Symberix Recent Developments
  97. 8.17 OpenBiome
  98. 8.17.1 OpenBiome Company Information
  99. 8.17.2 OpenBiome Business Overview
  100. 8.17.3 OpenBiome Microbiome Therapeutics Revenue and Gross Margin (2021-2026)
  101. 8.17.4 OpenBiome Microbiome Therapeutics Product Portfolio
  102. 8.17.5 OpenBiome Recent Developments
  103. 8.18 Azitra
  104. 8.18.1 Azitra Company Information
  105. 8.18.2 Azitra Business Overview
  106. 8.18.3 Azitra Microbiome Therapeutics Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Azitra Microbiome Therapeutics Product Portfolio
  108. 8.18.5 Azitra Recent Developments
  109. 8.19 Symbiotix Biotherapies
  110. 8.19.1 Symbiotix Biotherapies Company Information
  111. 8.19.2 Symbiotix Biotherapies Business Overview
  112. 8.19.3 Symbiotix Biotherapies Microbiome Therapeutics Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Symbiotix Biotherapies Microbiome Therapeutics Product Portfolio
  114. 8.19.5 Symbiotix Biotherapies Recent Developments
  115. 8.20 Osel
  116. 8.20.1 Osel Company Information
  117. 8.20.2 Osel Business Overview
  118. 8.20.3 Osel Microbiome Therapeutics Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Osel Microbiome Therapeutics Product Portfolio
  120. 8.20.5 Osel Recent Developments
  121. 8.21 Metabogen
  122. 8.21.1 Metabogen Company Information
  123. 8.21.2 Metabogen Business Overview
  124. 8.21.3 Metabogen Microbiome Therapeutics Revenue and Gross Margin (2021-2026)
  125. 8.21.4 Metabogen Microbiome Therapeutics Product Portfolio
  126. 8.21.5 Metabogen Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst